Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, Micol JB; UNIHEM, French Network of Pharmacovigilance Centers, ALFA, FILO, and GFM. Marmouset V, et al. Among authors: pages a. Clin Cancer Res. 2022 Dec 1;28(23):5211-5220. doi: 10.1158/1078-0432.CCR-22-1622. Clin Cancer Res. 2022. PMID: 36201165
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial.
Rodriguez J, Baldini C, Bayle A, Pages A, Danlos FX, Vasseur D, Rouleau E, Lacroix L, Alonso de Castro B, Goldschmidt V, Seknazi L, Hollebecque A, Michot JM, Champiat S, Marabelle A, Ouali K, Marzac C, Ponce S, Micol JB, Chaput N, Massard C, Italiano A. Rodriguez J, et al. Among authors: pages a. JCO Precis Oncol. 2024 May;8:e2300631. doi: 10.1200/PO.23.00631. JCO Precis Oncol. 2024. PMID: 38815178 Clinical Trial.
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders.
Fandrei D, Pegliasco J, Pasquier F, Ibrahim N, Kfoury M, Berthon C, Heiblig M, Lebon D, Marçais A, Meunier M, Al Jijakli A, Lemasle E, Chantepie S, Pautas C, Dumas PY, Salanoubat C, Carp D, Loyaux R, Quivoron C, Pages A, Job B, Jelin R, Jules-Clement G, Antony-Debré I, Renneville A, Cotteret S, Itzykson R, Dombret H, Duployez N, Droin N, Leary A, Marzac C, Bernard E, Micol JB. Fandrei D, et al. Among authors: pages a. Clin Cancer Res. 2025 Jun 3;31(11):2241-2253. doi: 10.1158/1078-0432.CCR-24-3683. Clin Cancer Res. 2025. PMID: 40162927
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.
Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C. Willekens C, et al. Among authors: pages a. Blood Cancer J. 2025 Apr 17;15(1):68. doi: 10.1038/s41408-025-01269-x. Blood Cancer J. 2025. PMID: 40246832 Free PMC article.
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma.
Quivoron C, Tarabay A, Michot JM, Pagès A, Lecourt H, Aupérin A, Danu A, Lazarovici J, Rossignol J, Ghez D, Dartigues P, Vergé V, Massard C, Camara-Clayette V, Ribrag V, Sarkozy C. Quivoron C, et al. Among authors: pages a. Haematologica. 2022 Aug 1;107(8):1928-1932. doi: 10.3324/haematol.2021.280464. Haematologica. 2022. PMID: 35320922 Free PMC article. No abstract available.
Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm.
Khalife-Hachem S, Pages A, Akoury E, Bonnet S, Birsen R, Busquet C, Contejean A, Danu A, de Botton S, de Charette M, Dumas PY, Jaccard A, Marfaing-Koka A, Willekens C, Deconinck E, Ghez D. Khalife-Hachem S, et al. Among authors: pages a. Blood Adv. 2025 Feb 25;9(4):793-796. doi: 10.1182/bloodadvances.2024014590. Blood Adv. 2025. PMID: 39642332 Free PMC article. No abstract available.
Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France.
Bigenwald C, Roos-Weil D, Pagès A, Hélias-Rodzewicz Z, Copie-Bergman C, Nashvi M, Khneisser P, Parrens M, Traverse-Glehen A, Ray-Coquard I, Ysebaert L, Marchand T, Razanamahery J, Charlotte F, Neel A, Damaj G, Dion J, Nazal-Traissac EM, Tardy S, Salmeron G, Monjanel H, Idbaih A, Héritier S, Haroche J, Donadieu J, Emile JF. Bigenwald C, et al. Among authors: pages a. Blood Adv. 2025 May 27;9(10):2530-2541. doi: 10.1182/bloodadvances.2024015208. Blood Adv. 2025. PMID: 40009752 Free PMC article.
426 results